Phadia adds Biomonitor's iLite tech to antidrug antibody testing business
This article was originally published in Clinica
Executive Summary
In line with its recent decision to expand into the antidrug antibody (ADA) testing market, Phadia has struck a deal with Danish biotech firm Biomonitor to gain access to the latter's cell-based ADA measurement technology.